Malta - English - Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - milrinone - solution for infusion or injection - milrinone 1 mg/ml - cardiac therapy

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - milrinone lactate 1.43 mg/ml equivalent to milrinone 1 mg/ml - concentrate for injection - 1 mg/ml - active: milrinone lactate 1.43 mg/ml equivalent to milrinone 1 mg/ml excipient: glucose lactic acid sodium hydroxide water for injection - milrinone-baxter is indicated for the short term intravenous therapy of severe congestive heart failure. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics.

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - milrinone 1 mg/ml - concentrate for injection - 1 mg/ml - active: milrinone 1 mg/ml excipient: glucose lactic acid sodium hydroxide water for injection - milrinone is indicated for the short term intravenous therapy of severe congestive heart failure. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. also indicated for low output states following cardiac surgery, including weaning from cardio-pulmonary bypass pump.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - milrinone 1.43 mg/ml (as lactate. equivalent to 1mg/ml milrinone) - solution for injection - 1 mg/ml - active: milrinone 1.43 mg/ml (as lactate. equivalent to 1mg/ml milrinone) excipient: glucose monohydrate lactic acid sodium hydroxide water for injection - primacor injection is indicated for the short term intravenous therapy of severe congestive heart failure. the majority of experience with intravenous primacor has been in patients receiving digoxin and diuretics. primacor is also indicated for low output states following cardiac surgery, including weaning from cardio-pulmonary bypass pump.

Ireland - English - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd - milrinone - solution for injection/infusion - 1 milligram(s)/millilitre - phosphodiesterase inhibitors; milrinone

Ireland - English - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - milrinone - solution for injection/infusion - 1 milligram(s)/millilitre - phosphodiesterase inhibitors; milrinone

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - milrinone, quantity: 10 mg - injection, concentrated - excipient ingredients: glucose; water for injections; sodium hydroxide; lactic acid - milrinone-baxter is indicated for the short term (48 hours) intravenous therapy of severe congestive heart failure patients in intensive care and coronary care units not responding to other therapy (e.g. digoxin, diuretics, vasodilators, including ace inhibitors). the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. ,milrinone-baxter is also indicated for low output states following cardiac surgery, including weaning from cardio-pulmonary bypass pump.

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7) - milrinone lactate 10 mg in 10 ml - milrinone lactate injection, usp and milrinone lactate in 5% dextrose injection are indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. the facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone lactate injection, usp and milrinone lactate in 5% dextrose injection are contraindicated in patients who are hypersensitive to it.

Malta - English - Medicines Authority

wockhardt uk limited - milrinone - solution for infusion or injection - milrinone 1 mg/ml - cardiac therapy

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7) - milrinone 0.2 mg in 1 ml - milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. the facility for immediate treatment of potential cardiac events, which may include life-threatening ventricular arrythmias, must be available. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone is contraindicated in patients who are hypersensitive to it. solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.